Table 1.
Summary of Selected Clinical Trials of Microbe-Targeted Therapies in IBDs
UC | CD | Pouchitis | ||||
---|---|---|---|---|---|---|
| ||||||
Benefit | Trial Design | Benefit | Trial Design | Benefit | Trial Design | |
| ||||||
FMT | − + |
RCT [18] Case Series [14,15] |
+ | Case Series [17] | ||
| ||||||
Antibiotics | ||||||
• Ciprofloxacin/Metronidazole | +/− | RCT [44,45] | + (colonic/perianal) | RCT [26–28] | + | RCT [52,53] |
• Rifaximin | − | RCT [57] | + (colonic) | RCT [30] | − | RCT [54] |
• Broad Spectrum | + | RCT [46,48] | ||||
| ||||||
Probiotics | ||||||
• VSL#3 | + | RCT [67,68] | − | RCT [74] | + | RCT [80,83] |
• Other | − | RCT [66] | − | RCT [71–73] | − | RCT [85] |
| ||||||
Prebiotics | − | RCT [93] | − | RCT [92,95] | − | RCT [96] |